©2022 Stanford Medicine
Study of Aspirin in Patients With Vestibular Schwannoma
Trial ID: NCT03079999
This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.
Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas
- Radiographic diagnosis of vestibular schwannoma (NF2-associated or sporadic).
- Age≥12 years.
- Ability to provide informed consent.Pediatric patients must provide assent in addition
to their parents'/guardians' consent. Adult patients who cannot consent for themselves
will not be eligible to participate in this study.
- Ability to swallow tablets.
- Inability to perform volumetric measurements of vestibular schwannoma(s).
- Inability to tolerate MRI with contrast.
- Daily use of aspirin within the last two months. Occasional use of aspirin for pain
relief is not exclusionary.
- Known allergy to aspirin.
- Impairment of gastrointestinal function or gastrointestinal disease that may
significantly alter the absorption of aspirin.
- Pregnant or lactating women.
- Patients with serious medical illnesses (e.g. severe asthma) that in the option of the
investigator could prevent participation in the trial.
- Active bleeding diathesis.
- Hydrocephalus from brainstem compression.
- Febrile illness or flu-like illness in children and adolescents less than 18 years of